Targeting HIV Entry: 3rd International Workshop

Conference Reports for NATAP


Targeting HIV Entry: 3rd International Workshop Washington, DC December 7-9, 2007

	Preclinical Work Suggests Advantages of New Fusion Inhibitor Versus Enfuvirtide - (12/12/07) Analysis of the Protease Inhibitor/Reverse Transcriptase Inhibitor/Fusion Inhibitor Resistance Pattern of Treatment-emergent CXCR4-using Virus from Six Patients in the MOTIVATE Studies Shows no Evidence of Different Drug Resistance Profiles Being Archived in the CCR5-tropic versus CXCR4-using Populations - (12/11/07) Viruses Utilizing Both CCR5 and CXCR4 Are Found in 5-13% of Acute HIV-1 Infections - (12/11/07) Characterization of Maraviroc Resistance in Patients Failing Treatment with CCR5-Tropic Virus in MOTIVATE 1 and 2 - (12/11/07) Correlates of Coreceptor Tropism in Three Large Cohorts: Does lower CD4 predict tropism switch? - (12/09/07) Correlates of Coreceptor Tropism in Three Large Cohorts: Does lower CD4 predict tropism switch? - (12/09/07) CXCR4-Using HIV Found in 8.5% During Early HIV Infection - (12/09/07) New More Sensitive Monogram Tropism Assay; Tweaked Trofile Assay Stronger in Spotting Dual/Mixed-Tropic Virus - (12/09/07) Maraviroc Failure With X4 Virus Does Not Spur New Resistance to Other ARVs - (12/09/07) Enhancements to the Trofile HIV Co-receptor Tropism Assay Enable Improved Detection of CXCR4-using Subpopulations and Earlier Detection of CXCR4-using Viruses in Sequential Patient Samples - (12/09/07) Background Drugs and Low Maraviroc Levels Explain Resistance in MOTIVATE - (12/09/07) Preclinical Work Suggests Advantages of New Fusion Inhibitor Versus Enfuvirtide - (12/09/07)